Medically reviewed by Jay N. Yepuri, MD Eosinophilic esophagitis (EoE) occurs when white blood cells called eosinophils build ...

Dosing of the first patient in Phase 2b marks an important transition of the RESOLVE trial from a Phase 2a open-label study ...

The clinical-stage biotechnology company said Tuesday that the study will enroll at least 60 participants who will receive either one EP-104GI dose, two doses or a placebo. After six months, eligible ...

Doctors used to think that eosinophilic esophagitis was the same thing as acid reflux. Now they know that it’s not, and more people are being diagnosed than ever before.

Eosinophilic gastrointestinal diseases are exponentially more prevalent among patients with atopic diseases compared with the ...

Apogee Therapeutics, Inc.'s APG777 shows promising week-16 efficacy and dosing potential, targeting the AT market. Click for ...

Nat Clin Pract Gastroenterol Hepatol. 2006;3(5):285-289. In the adult population, eosinophilic esophagitis tends to be chronic, but stable, with no significant effect on morbidity or mortality ...

The dynamics of the eosinophilic esophagitis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as APT-1011 (Ellodi Pharmaceuticals ...

From acid reflux to immune reactions, esophagitis has many causes—learn about its symptoms, types, and the latest treatments available.

Discover a study that highlights dupilumab’s consistent efficacy in eosinophilic oesophagitis, even among patients with ...

Eosinophilic Esophagitis Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers GetNews - TGAM - GetNews - Tue Oct 29, 2024 ...

Eosinophilic esophagitis (EoE) is a chronic, inflammatory disorder of the esophagus. It occurs when immune cells called eosinophils cause inflammation in the lining of your esophagus.